Back to search

University of Minnesota

Investigation of membrane stabilizing copolymers as early therapy for muscular dystrophy

Abstract

dc:description.abstract

Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder caused by mutations in the dystrophin gene, resulting in the absence of functional dystrophin protein and muscle cell membrane instability. The ensuing membrane fragility triggers a cascade of pathological events, including increased susceptibility to contraction-induced membrane injury, inflammation, necrosis, and progressive muscle loss. Current therapeutic strategies largely focus on dystrophin-deficiency downstream consequences or genetic correction but remain limited in efficacy, accessibility, safety, and timing of intervention. This dissertation focuses on an alternative and underexplored therapeutic approach: directly stabilizing the muscle sarcolemma. The first part of this work is focused on the onset of membrane damage and immune infiltration in the mdx mouse model of DMD, during early postnatal development, a critical period previously under-characterized. Results show that serum creatine kinase (CK), a biomarker of membrane damage, increases sharply as early as postnatal day 15. Concurrently, mass cytometry reveals robust immune cell accumulation, particularly non-monocyte-derived macrophages, into dystrophin-deficient skeletal muscle. Systemic delivery of poloxamer 188 (P188), a first-in-class triblock copolymer, starting as early as postnatal day 1 or 2, significantly prevented CK elevation and reduced immune cell accumulation, demonstrating that early membrane stabilization can preempt both mechanical and inflammatory pathology. In the second part, a next-generation synthetic membrane stabilizer: a poly(ethylene oxide)/poly(propylene oxide)-based bottlebrush polymer was investigated. This molecule demonstrates ~150,000-fold greater potency than its linear analogs in restoring the contractile function of dystrophic myofibers in vitro. Remarkably, in vivo administration to mdx mice confers robust protection of limb and diaphragm muscles from structural damage and prevents stress-induced heart failure, indicating systemic efficacy across muscle groups. Collectively, this work identifies membrane stabilization as a disease-modifying strategy for DMD. Importantly, the demonstration of efficacy during the neonatal window lines up with the recent implementation of newborn screening for DMD, supporting a paradigm shift toward early intervention before irreversible muscle damage occurs. These findings have broad therapeutic implications beyond DMD, offering a versatile and translatable approach for treating a range of inherited and acquired diseases characterized by sarcolemma fragility.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Cohen, Houda

Subjects

dc:subject × 3

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*
Dc Identifier Citation
Cohen, Houda. (2025). Investigation of membrane stabilizing copolymers as early therapy for muscular dystrophy. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/279792.

Chain of custody

source
Harvested from
University of Minnesota
Base URL
conservancy.umn.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Cohen, Houda. Investigation of membrane stabilizing copolymers as early therapy for muscular dystrophy. 2025. https://hdl.handle.net/11299/279792